Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Gallant Pet Inc. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, RAHMAN, MASUDUR, indicating a concentrated prosecution focus at this stage. The presence of only 1 distinct art unit suggests that the company's current patent activity is localized within a specific technical niche. Practitioners should note that such a narrow distribution limits the variety of examiner perspectives encountered across the portfolio.
The busiest examiner, RAHMAN, MASUDUR, is responsible for 1 pending office action, which represents the entirety of the company's pending workload. For a practitioner, this means that the outcome of the portfolio's current examination phase rests with a single individual. The alignment between the 1 distinct examiner and the previously mentioned art unit confirms a streamlined interaction with the patent office. This concentration allows for a specific prosecution strategy but increases the impact of an individual examiner's tendencies on the overall portfolio status.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RAHMAN, MASUDUR | 1 | 72.9% | +31.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18707117 | PRIMED UTERINE-DERIVED REGENERATIVE CELL COMPOSITIONS AND USES THEREOF | RAHMAN, MASUDUR | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18707117 | PRIMED UTERINE-DERIVED REGENERATIVE CELL COMPOSITIONS AND USES THEREOF | RAHMAN, MASUDUR | — |
| Art Unit | Apps |
|---|---|
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18707117 | PRIMED UTERINE-DERIVED REGENERATIVE CELL COMPOSITIONS AND USES THEREOF | RAHMAN, MASUDUR | 1633 | §103§112 | Non-Final OA | — | Pending | May 02, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGallant Pet Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Masudur Rahman has the most, with 1 of Gallant Pet Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
